BioSpace News Archive

AltruBio Inc. today announced that management will participate in the following May 2024 medical conferences.

Akari Therapeutics, Plc and Peak Bio Inc. announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC platform technology and Akari’s PAS-nomacopan Geographic Atrophy program.

Avalyn Pharma Inc. today announced that Douglas Carlson has been appointed chief financial officer and chief business officer.

PharmaTher Holdings Ltd. announced today Sairiyo Therapeutics Inc. has completed its clinical and regulatory package to evaluate Sairiyo’s patented reformulated enteric coated version of orally bioavailable cepharanthine (“PD-001”) as a potential treatment for infectious diseases and oncology in a Phase1 clinical study in Australia.

Ardelyx, Inc. today announced that additional data supporting XPHOZAH ® (tenapanor) will be presented at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, to be held May 14-18, 2024, in Long Beach, California.

Tevogen Bio Holdings Inc. announced financial results for full year 2023, business highlights, and upcoming operational objectives.

Aadi Bioscience, Inc. today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024.

Hoth Therapeutics, Inc. is scheduled to attend the EF Hutton Annual Global Conference in New York, NY.

RS Oncology today announced that it will present the complete Phase 1 dose escalation data as an oral presentation at the world’s largest oncology meeting, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced its first-quarter 2024 financial results.